Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line
- PMID: 1670924
- DOI: 10.1210/endo-128-1-13
Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line
Abstract
GH3 cells are a clonal strain from a rat pituitary tumor that synthesizes and secretes both PRL and GH. The peculiarity of these cells is that they do not express receptors for dopamine; thus the hormone release is insensitive to the inhibitory effect of dopamine and D2 receptor agonists. Exposure of GH3 cells to epidermal growth factor for 4 consecutive days markedly altered the cell morphology, from a spherical appearance to an elongated flattened shape, and increased the cell size. These morphological changes were accompanied by the functional expression of D2 dopamine receptors as shown by the presence of a specific, saturable, and stereoselective high affinity binding for [3H]spiroperidol in epidermal growth factor-treated cells and by the fact that the selective D2 agonist quinpirole recovered the property to inhibit PRL secretion in the cell cultures exposed to the neurotrophic factor. The effect of EGF on the functional expression of D2 receptors was dose dependent (EC50 = 8 pM) and reversible. These data suggest that EGF elicits major effects on the expression of specific genes leading to the differentiation of GH3 cells into lactotroph-like cells endowed with dopamine D2 receptors.
Similar articles
-
Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.Endocrinology. 1989 Jan;124(1):346-55. doi: 10.1210/endo-124-1-346. Endocrinology. 1989. PMID: 2521206
-
Stimulatory effects of quinpirole hydrochloride, D2-dopamine receptor agonist, at low concentrations on prolactin release in female rats in vitro.Life Sci. 1992;51(10):727-32. doi: 10.1016/0024-3205(92)90481-4. Life Sci. 1992. PMID: 1355255
-
Absence of high affinity dopamine receptor in GH3 cells: a prolactin-secreting clone resistant to the inhibitory action of dopamine.Endocrinology. 1980 Mar;106(3):718-23. doi: 10.1210/endo-106-3-718. Endocrinology. 1980. PMID: 7353539
-
Dopamine, the dopamine D2 receptor and pituitary tumours.Clin Endocrinol (Oxf). 1991 Dec;35(6):455-66. doi: 10.1111/j.1365-2265.1991.tb00928.x. Clin Endocrinol (Oxf). 1991. PMID: 1837503 Review.
-
[Coupling of metabotropic receptors to ionic channels. Role of G-proteins].C R Seances Soc Biol Fil. 1993;187(1):7-13. C R Seances Soc Biol Fil. 1993. PMID: 7694780 Review. French.
Cited by
-
Pharmacological and molecular basis for dopamine D-2 receptor diversity.Mol Neurobiol. 1990 Fall-Winter;4(3-4):181-96. doi: 10.1007/BF02780340. Mol Neurobiol. 1990. PMID: 2135394 Review.
-
Expression of Growth Factors in Normal and Neoplastic Pituitary Tissues.Endocr Pathol. 2000 Winter;11(4):295-300. doi: 10.1385/ep:11:4:295. Endocr Pathol. 2000. PMID: 12114754
-
Water Extract of Fructus Hordei Germinatus Shows Antihyperprolactinemia Activity via Dopamine D2 Receptor.Evid Based Complement Alternat Med. 2014;2014:579054. doi: 10.1155/2014/579054. Epub 2014 Aug 28. Evid Based Complement Alternat Med. 2014. PMID: 25254056 Free PMC article.
-
Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs.Endocrinology. 2009 Feb;150(2):795-802. doi: 10.1210/en.2008-0756. Epub 2008 Oct 1. Endocrinology. 2009. PMID: 18832099 Free PMC article.
-
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.BMC Endocr Disord. 2021 Nov 23;21(1):235. doi: 10.1186/s12902-021-00900-9. BMC Endocr Disord. 2021. PMID: 34814904 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources